Torrent Pharmaceuticals

TORNTPHARM.NS

Ahmedabad, India· Est. 1959

torrentpharma.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

TORNTPHARM.NS · Stock Price

INR 4,362.70+1221.50 (+38.89%)

Market Cap: $15.7B

Historical price data

Market Cap: $15.7BPipeline: 72 drugs (3 Phase 3)Patents: 20Founded: 1959Employees: 10,000+HQ: Ahmedabad, India

Sector Ranking#8 in Small Molecule Drugs #3 in Drug Delivery & Formulation

Overview

Torrent Pharmaceuticals is a mission-driven, revenue-generating leader in the global branded generics market, focused on improving patient access to high-quality, complex medicines. Its core strategy of therapeutic area specialization and geographic diversification has yielded market leadership in India, Brazil, and Germany, supported by a robust manufacturing and R&D infrastructure. The company is executing a growth strategy centered on expanding its portfolio of complex generics, biosimilars, and consumer healthcare brands while maintaining a strong commitment to sustainability and ESG principles.

CardiovascularCentral Nervous SystemGastro-IntestinalWomen's HealthcareDiabetologyOncologyNephrologyAnti-Microbial

Technology Platform

Integrated platform specializing in complex formulations, novel drug delivery systems (sustained-release, fixed-dose combinations), and biosimilars development, supported by globally compliant manufacturing infrastructure.

Pipeline

72 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
TRC041266 + Placebo	Chronic Stable Heart Failure	Phase 3
Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) + ACZONE® (da...	Acne Vulgaris	Phase 3
TRC150094 + Placebo	Diabetes	Phase 3
TRC150094	Metabolic Cardiovascular Syndrome	Phase 1/2
Losartan Potassium Tablets	Healthy	Phase 1

FDA Approved Drugs

FIDAXOMICINANDAJan 27, 2026

LAMOTRIGINEANDAJan 8, 2026

NILOTINIB HYDROCHLORIDEANDADec 15, 2025

Opportunities

The global shift towards affordable complex generics and biosimilars, combined with supply chain diversification trends, presents a significant tailwind.

Torrent's established leadership in chronic therapy areas in India and key international markets like Brazil and Germany provides a strong platform for capturing this growth.

Risk Factors

The company faces intense regulatory scrutiny across its global manufacturing network and persistent pricing pressure in the generics industry.

Execution risks in its biosimilars pipeline and geopolitical volatility in key operational regions are additional challenges.

Competitive Landscape

Torrent competes with large Indian pharma peers domestically and global generics giants internationally. Its differentiation lies in a niche-focused therapeutic strategy, deep market penetration in select geographies (Brazil, Germany), and a growing portfolio of complex, value-added products.